Chapter/Section Purchase

1 Osteoarthritis Pain Drugs Market Overview
1.1 Product Overview and Scope of Osteoarthritis Pain Drugs
1.2 Osteoarthritis Pain Drugs Segment by Type
1.2.1 Global Osteoarthritis Pain Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Oral
1.2.3 Injection
1.2.4 External
1.3 Osteoarthritis Pain Drugs Segment by Application
1.3.1 Global Osteoarthritis Pain Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Medical Care
1.3.3 Personal Care
1.4 Global Osteoarthritis Pain Drugs Market Size Estimates and Forecasts
1.4.1 Global Osteoarthritis Pain Drugs Revenue 2016-2027
1.4.2 Global Osteoarthritis Pain Drugs Sales 2016-2027
1.4.3 Osteoarthritis Pain Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Osteoarthritis Pain Drugs Market Competition by Manufacturers
2.1 Global Osteoarthritis Pain Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Osteoarthritis Pain Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Osteoarthritis Pain Drugs Manufacturing Sites, Area Served, Product Type
2.5 Osteoarthritis Pain Drugs Market Competitive Situation and Trends
2.5.1 Osteoarthritis Pain Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Osteoarthritis Pain Drugs Players Market Share by Revenue
2.5.3 Global Osteoarthritis Pain Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Osteoarthritis Pain Drugs Retrospective Market Scenario by Region
3.1 Global Osteoarthritis Pain Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Osteoarthritis Pain Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Osteoarthritis Pain Drugs Market Facts & Figures by Country
3.3.1 North America Osteoarthritis Pain Drugs Sales by Country
3.3.2 North America Osteoarthritis Pain Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Osteoarthritis Pain Drugs Market Facts & Figures by Country
3.4.1 Europe Osteoarthritis Pain Drugs Sales by Country
3.4.2 Europe Osteoarthritis Pain Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Osteoarthritis Pain Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Osteoarthritis Pain Drugs Sales by Region
3.5.2 Asia Pacific Osteoarthritis Pain Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Osteoarthritis Pain Drugs Market Facts & Figures by Country
3.6.1 Latin America Osteoarthritis Pain Drugs Sales by Country
3.6.2 Latin America Osteoarthritis Pain Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Osteoarthritis Pain Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Osteoarthritis Pain Drugs Sales by Country
3.7.2 Middle East and Africa Osteoarthritis Pain Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Osteoarthritis Pain Drugs Historic Market Analysis by Type
4.1 Global Osteoarthritis Pain Drugs Sales Market Share by Type (2016-2021)
4.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Osteoarthritis Pain Drugs Price by Type (2016-2021)

5 Global Osteoarthritis Pain Drugs Historic Market Analysis by Application
5.1 Global Osteoarthritis Pain Drugs Sales Market Share by Application (2016-2021)
5.2 Global Osteoarthritis Pain Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Osteoarthritis Pain Drugs Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Pfizer Osteoarthritis Pain Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Bayer Osteoarthritis Pain Drugs Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 SK Chemicals
6.3.1 SK Chemicals Corporation Information
6.3.2 SK Chemicals Description and Business Overview
6.3.3 SK Chemicals Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 SK Chemicals Osteoarthritis Pain Drugs Product Portfolio
6.3.5 SK Chemicals Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GSK Osteoarthritis Pain Drugs Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Sanofi Osteoarthritis Pain Drugs Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Crystal Genomics
6.6.1 Crystal Genomics Corporation Information
6.6.2 Crystal Genomics Description and Business Overview
6.6.3 Crystal Genomics Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Crystal Genomics Osteoarthritis Pain Drugs Product Portfolio
6.6.5 Crystal Genomics Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Johnson & Johnson Osteoarthritis Pain Drugs Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Sino Biopharmaceutical
6.8.1 Sino Biopharmaceutical Corporation Information
6.8.2 Sino Biopharmaceutical Description and Business Overview
6.8.3 Sino Biopharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Sino Biopharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.8.5 Sino Biopharmaceutical Recent Developments/Updates
6.9 Haohai Biological
6.9.1 Haohai Biological Corporation Information
6.9.2 Haohai Biological Description and Business Overview
6.9.3 Haohai Biological Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Haohai Biological Osteoarthritis Pain Drugs Product Portfolio
6.9.5 Haohai Biological Recent Developments/Updates
6.10 Zhejiang Chengyi Pharmaceutical
6.10.1 Zhejiang Chengyi Pharmaceutical Corporation Information
6.10.2 Zhejiang Chengyi Pharmaceutical Description and Business Overview
6.10.3 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Zhejiang Chengyi Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.10.5 Zhejiang Chengyi Pharmaceutical Recent Developments/Updates
6.11 Freda
6.11.1 Freda Corporation Information
6.11.2 Freda Osteoarthritis Pain Drugs Description and Business Overview
6.11.3 Freda Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Freda Osteoarthritis Pain Drugs Product Portfolio
6.11.5 Freda Recent Developments/Updates
6.12 Bright Future
6.12.1 Bright Future Corporation Information
6.12.2 Bright Future Osteoarthritis Pain Drugs Description and Business Overview
6.12.3 Bright Future Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Bright Future Osteoarthritis Pain Drugs Product Portfolio
6.12.5 Bright Future Recent Developments/Updates
6.13 Jingfeng Pharmaceutical
6.13.1 Jingfeng Pharmaceutical Corporation Information
6.13.2 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.13.3 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Jingfeng Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.13.5 Jingfeng Pharmaceutical Recent Developments/Updates
6.14 Chugai Pharmaceutical
6.14.1 Chugai Pharmaceutical Corporation Information
6.14.2 Chugai Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.14.3 Chugai Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Chugai Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.14.5 Chugai Pharmaceutical Recent Developments/Updates
6.15 Mikasa Seiyaku
6.15.1 Mikasa Seiyaku Corporation Information
6.15.2 Mikasa Seiyaku Osteoarthritis Pain Drugs Description and Business Overview
6.15.3 Mikasa Seiyaku Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Mikasa Seiyaku Osteoarthritis Pain Drugs Product Portfolio
6.15.5 Mikasa Seiyaku Recent Developments/Updates
6.16 Taisho Pharmaceutical
6.16.1 Taisho Pharmaceutical Corporation Information
6.16.2 Taisho Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.16.3 Taisho Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Taisho Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.16.5 Taisho Pharmaceutical Recent Developments/Updates
6.17 Seikagaku Corporation
6.17.1 Seikagaku Corporation Corporation Information
6.17.2 Seikagaku Corporation Osteoarthritis Pain Drugs Description and Business Overview
6.17.3 Seikagaku Corporation Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Seikagaku Corporation Osteoarthritis Pain Drugs Product Portfolio
6.17.5 Seikagaku Corporation Recent Developments/Updates
6.18 GlaxoSmithKline
6.18.1 GlaxoSmithKline Corporation Information
6.18.2 GlaxoSmithKline Osteoarthritis Pain Drugs Description and Business Overview
6.18.3 GlaxoSmithKline Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.18.4 GlaxoSmithKline Osteoarthritis Pain Drugs Product Portfolio
6.18.5 GlaxoSmithKline Recent Developments/Updates
6.19 Eli Lilly
6.19.1 Eli Lilly Corporation Information
6.19.2 Eli Lilly Osteoarthritis Pain Drugs Description and Business Overview
6.19.3 Eli Lilly Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.19.4 Eli Lilly Osteoarthritis Pain Drugs Product Portfolio
6.19.5 Eli Lilly Recent Developments/Updates
6.20 Novartis
6.20.1 Novartis Corporation Information
6.20.2 Novartis Osteoarthritis Pain Drugs Description and Business Overview
6.20.3 Novartis Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.20.4 Novartis Osteoarthritis Pain Drugs Product Portfolio
6.20.5 Novartis Recent Developments/Updates
6.21 Horizon Pharma
6.21.1 Horizon Pharma Corporation Information
6.21.2 Horizon Pharma Osteoarthritis Pain Drugs Description and Business Overview
6.21.3 Horizon Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.21.4 Horizon Pharma Osteoarthritis Pain Drugs Product Portfolio
6.21.5 Horizon Pharma Recent Developments/Updates
6.22 Abbott
6.22.1 Abbott Corporation Information
6.22.2 Abbott Osteoarthritis Pain Drugs Description and Business Overview
6.22.3 Abbott Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.22.4 Abbott Osteoarthritis Pain Drugs Product Portfolio
6.22.5 Abbott Recent Developments/Updates
6.23 Mylan
6.23.1 Mylan Corporation Information
6.23.2 Mylan Osteoarthritis Pain Drugs Description and Business Overview
6.23.3 Mylan Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.23.4 Mylan Osteoarthritis Pain Drugs Product Portfolio
6.23.5 Mylan Recent Developments/Updates
6.24 Daiichi Sankyo
6.24.1 Daiichi Sankyo Corporation Information
6.24.2 Daiichi Sankyo Osteoarthritis Pain Drugs Description and Business Overview
6.24.3 Daiichi Sankyo Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.24.4 Daiichi Sankyo Osteoarthritis Pain Drugs Product Portfolio
6.24.5 Daiichi Sankyo Recent Developments/Updates
6.25 TEVA
6.25.1 TEVA Corporation Information
6.25.2 TEVA Osteoarthritis Pain Drugs Description and Business Overview
6.25.3 TEVA Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.25.4 TEVA Osteoarthritis Pain Drugs Product Portfolio
6.25.5 TEVA Recent Developments/Updates
6.26 Almatica Pharma
6.26.1 Almatica Pharma Corporation Information
6.26.2 Almatica Pharma Osteoarthritis Pain Drugs Description and Business Overview
6.26.3 Almatica Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.26.4 Almatica Pharma Osteoarthritis Pain Drugs Product Portfolio
6.26.5 Almatica Pharma Recent Developments/Updates
6.27 Astellas Pharma
6.27.1 Astellas Pharma Corporation Information
6.27.2 Astellas Pharma Osteoarthritis Pain Drugs Description and Business Overview
6.27.3 Astellas Pharma Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.27.4 Astellas Pharma Osteoarthritis Pain Drugs Product Portfolio
6.27.5 Astellas Pharma Recent Developments/Updates
6.28 Tide Pharmaceutical
6.28.1 Tide Pharmaceutical Corporation Information
6.28.2 Tide Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.28.3 Tide Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.28.4 Tide Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.28.5 Tide Pharmaceutical Recent Developments/Updates
6.29 Iroko Pharmaceuticals
6.29.1 Iroko Pharmaceuticals Corporation Information
6.29.2 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Description and Business Overview
6.29.3 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.29.4 Iroko Pharmaceuticals Osteoarthritis Pain Drugs Product Portfolio
6.29.5 Iroko Pharmaceuticals Recent Developments/Updates
6.30 Hengrui Pharmaceutical
6.30.1 Hengrui Pharmaceutical Corporation Information
6.30.2 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Description and Business Overview
6.30.3 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Sales, Revenue and Gross Margin (2016-2021)
6.30.4 Hengrui Pharmaceutical Osteoarthritis Pain Drugs Product Portfolio
6.30.5 Hengrui Pharmaceutical Recent Developments/Updates

7 Osteoarthritis Pain Drugs Manufacturing Cost Analysis
7.1 Osteoarthritis Pain Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Osteoarthritis Pain Drugs
7.4 Osteoarthritis Pain Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Osteoarthritis Pain Drugs Distributors List
8.3 Osteoarthritis Pain Drugs Customers

9 Osteoarthritis Pain Drugs Market Dynamics
9.1 Osteoarthritis Pain Drugs Industry Trends
9.2 Osteoarthritis Pain Drugs Growth Drivers
9.3 Osteoarthritis Pain Drugs Market Challenges
9.4 Osteoarthritis Pain Drugs Market Restraints

10 Global Market Forecast
10.1 Osteoarthritis Pain Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Osteoarthritis Pain Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Osteoarthritis Pain Drugs by Type (2022-2027)
10.2 Osteoarthritis Pain Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Osteoarthritis Pain Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Osteoarthritis Pain Drugs by Application (2022-2027)
10.3 Osteoarthritis Pain Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Osteoarthritis Pain Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Osteoarthritis Pain Drugs by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer